Andere Kunden interessierten sich auch für
![Exploring the State of the Science of Stem Cell Transplantation and Posttransplant Disability]( "Exploring the State of the Science of Stem Cell Transplantation and Posttransplant Disability")
Exploring the State of the Science of Stem Cell Transplantation and Posttransplant Disability39,99 €![Current Issues in the Assessment of Respiratory Protective Devices for Occupational and Non-Occupational Uses]( "Current Issues in the Assessment of Respiratory Protective Devices for Occupational and Non-Occupational Uses")
Current Issues in the Assessment of Respiratory Protective Devices for Occupational and Non-Occupational Uses72,99 €![The Role of Digital Health Technologies in Drug Development]( "The Role of Digital Health Technologies in Drug Development")
The Role of Digital Health Technologies in Drug Development69,99 €![Addressing the Adverse Consequences of Cancer Treatment]( "Addressing the Adverse Consequences of Cancer Treatment")
Addressing the Adverse Consequences of Cancer Treatment44,99 €![Exploring the State of the Science of Solid Organ Transplantation and Disability]( "Exploring the State of the Science of Solid Organ Transplantation and Disability")
Exploring the State of the Science of Solid Organ Transplantation and Disability48,99 €![Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System]( "Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System")
Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System23,99 €![The Drug Development Paradigm in Oncology]( "The Drug Development Paradigm in Oncology")
The Drug Development Paradigm in Oncology59,99 €
As part of the overall disability determination process, the Social Security Administration uses a step-by-step approach to understand how severe an individual's condition is and whether it meets program criteria for disability. The use of various types of biomarkers has been suggested as a way to strengthen the amount and quality of objective evidence available to the review process. At the request of the Social Security Administration, the National Academies of Sciences, Engineering, and Medicine's Board on Health Care Services organized a virtual workshop on July 21, 2020, titled The State of the Science of the Use of Biomarkers to Establish the Presence and Severity of Impairments. Workshop discussions focused on the current and potential uses for biomarkers; explored legal and ethical implications associated with biomarker use in clinical decision making; and considered the possible uses of nongenetic biomarkers as tools for the diagnosis or prognosis of the severity of specific physical and mental impairments. This publication summarizes the presentations and discussion of the workshop.